Health Condition 1: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation
Conditions
Interventions
Intervention1: Vonaprazan: Intervention drugs: Vonoprazan 20mg + Amoxicillin 750 mg + Metronidazole 400mg twice daily for 14 days, PO
Control Intervention1: Omeprazole: Omeprazole 20mg + Amoxicillin
Sponsors
Dr Bazla Nazir
Eligibility
Inclusion criteria
Inclusion criteria: Patients willing to provide informed consent and adhere to study protocols. Patients with a confirmed diagnosis of H. pylori infection via urea breath test, stool antigen test, or histological examination.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of allergy or intolerance to vonoprazan, omeprazole, or related compounds. 2.Patients currently using other proton pump inhibitors or H2 receptor antagonists within 2 weeks before the study. 3.Patients with a history of gastric surgery or previous H. pylori eradication therapy. 4.Patients with severe comorbidities such as liver, kidney, or heart diseases. 5.Pregnant or lactating women. 6.Patients unable or unwilling to comply with study procedures and follow-up visits
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients achieving clinical cure (resolution of peptic ulcer symptoms) at the end of pharmacotherapy (14th day) for Vonoprazan triple therapy compared to Omeprazole triple therapy.Timepoint: 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| H. pylori eradication (negative UBT and RUT post-treatment)Timepoint: baseline and 2 weeks;Endoscopic grading (Forrest Classification)Timepoint: baseline and 2 weeks;quality of life assessment using validated tool: SF-36Timepoint: 2 weeks;Incidence of adverse effects using WHO UMC causality assessment scalesTimepoint: baseline to 2 weeks | — |
Countries
India
Contacts
Public ContactDr Bazla Nazir
Indira Gandhi Institute Of Medical Sciences
Outcome results
None listed